IDP-118
Total Payments
$237,486
Transactions
96
Doctors
2
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $16,000 | 2 | 2 |
| 2017 | $221,486 | 94 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $237,486 | 96 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE 3, MULTICENTER, OPEN LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY OF IDP-118 LOTION IN THE TREATMENT OF PLAQUE PSORIASIS | Valeant Pharmaceuticals North America LLC | $113,292 | 0 |
| A PHASE 1B OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE ABSORPTION AND SYSTEMIC PHARMACOKINETICS AND HPA AXIS SUPPRESSION POTENTIAL OF TOPICALLY APPLIED IDP-118 LOTION AND HP MONAD LOTION IN SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS. | Valeant Pharmaceuticals North America LLC | $54,641 | 0 |
| A PHASE 3, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, VEHICLE CONTROLLED CLINICAL STUDY TO ASSESS THE SAFETY AND EFFICACY OF IDP-118 IN THE TREATMENT OF PLAQUE PSORIASIS | Valeant Pharmaceuticals North America LLC | $30,175 | 0 |
| A Phase 3, Multicenter, Open Label Study to Evaluate the Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis | Bausch Health US, LLC | $16,000 | 2 |
| A PHASE 2, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, VEHICLE-CONTROLLED STUDY TO COMPARE THE SAFETY AND EFFICACY OF IDP-118 LOTION TO ULTRAVATE IN THE TREATMENT OF PLAQUE PSORIASIS | Valeant Pharmaceuticals North America LLC | $12,445 | 0 |
| A PHASE 2, MULTICENTER, DOUBLE BLINDED, RANDOMIZED, VEHICLE CONTROLLED STUDY TO COMPARE THE SAFETY AND EFFICACY OF IDP-118 LOTION IN THE TREATMENT OF PLAQUE PSORIASIS | Valeant Pharmaceuticals North America LLC | $10,935 | 0 |
Ad
Manufacturing Companies
- Valeant Pharmaceuticals North America LLC $221,486
- Bausch Health US, LLC $16,000
Product Information
- Type Drug
- Total Payments $237,486
- Total Doctors 2
- Transactions 96
About IDP-118
IDP-118 is a drug associated with $237,486 in payments to 2 healthcare providers, recorded across 96 transactions in the CMS Open Payments database. The primary manufacturer is Valeant Pharmaceuticals North America LLC.
Payment data is available from 2017 to 2018. In 2018, $16,000 was paid across 2 transactions to 2 doctors.
The most common payment nature for IDP-118 is "Unspecified" ($237,486, 100.0% of total).
IDP-118 is associated with 6 research studies, including "A PHASE 3, MULTICENTER, OPEN LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY OF IDP-118 LOTION IN THE TREATMENT OF PLAQUE PSORIASIS" ($113,292).